


Foxy-5

Cat. No.:	HY-P1416
CAS No.:	881188-51-8
Molecular Formula:	C ₂₆ H ₄₂ N ₆ O ₁₂ S ₂
Molecular Weight:	694.77
Sequence:	Met-Asp-Gly-Cys-Glu-Leu
Sequence Shortening:	MDGCEL
Target:	Wnt
Pathway:	Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β -catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model ^{[1][2][3][4]} .
IC ₅₀ & Target	WNT5A ^[2]
In Vivo	Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model ^[1] . Foxy-5 reduces the number of colonic cancer stem cells in a xenograft mouse model of human colonic cancer ^[2] .

REFERENCES

- [1]. Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. *PLoS One*. 2017 Sep 8;12(9):e0184418.
- [2]. Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. *Anticancer Res*. 2019 Apr;39(4):1719-1728.
- [3]. Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. *PLoS One*. 2017 Sep 8;12(9):e0184418.
- [4]. Kelsey R. Prostate cancer: Foxy-5 in prostate cancer model. *Nat Rev Urol*. 2017 Nov;14(11):638.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA